The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net (loss) income | -412,781 |
| Depreciation and amortization | 5,177 |
| Stock-based compensation expense | 52,552 |
| Net accretion of discount on marketable securities | 7,195 |
| Gain on sale of contingent payments | 0 |
| Loss (gain) on disposal of property and equipment | -5 |
| Non-cash operating lease expense | 12,425 |
| Expense associated with license agreement | 10,000 |
| Realized gain on investments | 118 |
| Milestone payment from gain on sale of oncology business | 0 |
| Accounts receivable, net | 6,468 |
| Inventory | 5,304 |
| Prepaid expenses and other current and non-current assets | 3,172 |
| Accounts payable | 1,746 |
| Accrued expenses | -1,402 |
| Income taxes payable | -871 |
| Operating lease liabilities | -16,781 |
| Other liabilities | -790 |
| Net cash used in operating activities | -372,977 |
| Purchases of marketable securities | 641,759 |
| Proceeds from maturities and sales of marketable securities | 1,033,259 |
| Proceeds from sale of contingent payments | 0 |
| Proceeds from milestone payment from gain on sale of oncology business | 0 |
| Payments associated with license agreement | 10,000 |
| Purchases of property and equipment | 4,316 |
| Proceeds from sale of equipment | 0 |
| Net cash provided by investing activities | 377,184 |
| Net proceeds from stock option exercises and employee stock purchase plan | 8,676 |
| Net cash provided by financing activities | 8,676 |
| Net change in cash and cash equivalents | 12,883 |
| Cash and cash equivalents at beginning of period | 76,247 |
| Cash and cash equivalents at end of period | 89,130 |
AGIOS PHARMACEUTICALS, INC. (AGIO)
AGIOS PHARMACEUTICALS, INC. (AGIO)